ZA200201608B - Device housing for an aerosol container. - Google Patents
Device housing for an aerosol container. Download PDFInfo
- Publication number
- ZA200201608B ZA200201608B ZA200201608A ZA200201608A ZA200201608B ZA 200201608 B ZA200201608 B ZA 200201608B ZA 200201608 A ZA200201608 A ZA 200201608A ZA 200201608 A ZA200201608 A ZA 200201608A ZA 200201608 B ZA200201608 B ZA 200201608B
- Authority
- ZA
- South Africa
- Prior art keywords
- housing
- collar
- sleeve
- electrical device
- mechanical
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims description 55
- 238000000034 method Methods 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 34
- 238000003466 welding Methods 0.000 claims description 15
- 238000005304 joining Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 229960004017 salmeterol Drugs 0.000 claims description 7
- 238000004377 microelectronic Methods 0.000 claims description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 5
- 239000003380 propellant Substances 0.000 claims description 5
- 229960002052 salbutamol Drugs 0.000 claims description 5
- 229960000289 fluticasone propionate Drugs 0.000 claims description 4
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 3
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001361 ipratropium bromide Drugs 0.000 claims description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- -1 e.g. Chemical compound 0.000 description 21
- 230000007246 mechanism Effects 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 4
- 229910021653 sulphate ion Inorganic materials 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229950000339 xinafoate Drugs 0.000 description 4
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960004436 budesonide Drugs 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 238000005476 soldering Methods 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229960002714 fluticasone Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- UBLVUWUKNHKCJJ-ZSCHJXSPSA-N (2s)-2,6-diaminohexanoic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound NCCCC[C@H](N)C(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 UBLVUWUKNHKCJJ-ZSCHJXSPSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960003821 choline theophyllinate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- HNJJXZKZRAWDPF-UHFFFAOYSA-N methapyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 HNJJXZKZRAWDPF-UHFFFAOYSA-N 0.000 description 1
- 229960001869 methapyrilene Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- RLANKEDHRWMNRO-UHFFFAOYSA-M oxtriphylline Chemical compound C[N+](C)(C)CCO.O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 RLANKEDHRWMNRO-UHFFFAOYSA-M 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 125000000109 phenylethoxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Landscapes
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Description
DEVICE HOUSING FOR A AEROSOL CONTAINER
The present invention relates to a housing for a mechanical or electrical device which is joinable to a collar affixed around the neck of an aerosol canister to form a chemical dispenser. In particular, it relates to a medicament dispenser formable by welding a housing for a dose counter to a collar affixed around the neck of an aerosol canister.
Aerosol canisters are widely used in domestic, commercial and industrial situations for the application of a range of chemicals. Typical examples of chemical products which are dispensable in this way include cosmetics, health products, paints, pharmaceuticals and agrochemicals. Frequently there is a need to attach mechanical or electrical devices to such aerosol canisters, for example to regulate or record the flow of chemical from the canister, or to act as environmental sensors.
Such devices may be affixed to the canisters by a range of technologies including the use of adhesives and heat treatment, such as soldering or welding. However, the attachment of such devices to aerosol canisters poses difficulties in terms of producing a secure joint without affecting the integrity of the chemical by the application of excess heat during the heating or welding process. Similarly, the use of adhesives may lead to contamination problems due to the presence of low concentrations of volatiles from the adhesive on dispensing the chemical.
Medicament dispensers are extensively used in the administration of medicines, particularly those for the treatment of respiratory disorders. Medicaments which are
‘ PCT/EP00/09991 ) contained in an aerosol and are administered to a patient by means of an inhalation device are widely used in such therapy. These inhalation devices typically comprise a tubular housing or sleeve in which the aerosol canister is located and an outlet tube leading from the housing. The aerosol canisters used in such inhalation devices are designed to deliver a predetermined dose of medicament upon actuation; the valves can be opened either by depression of the valve member itself or by depression of the canister while the valve member is held stationary. In the use of such devices, the aerosol canister is placed in the tubular housing with the outlet valve member of the canister communicating via a support with the outlet tube, for example a nozzle or mouthpiece.
A recent development in this field of technology is the use of mechanical or electrical dose counters to register the number of medicament doses used or remaining within the medicament dispenser. Dose counters can be positioned within the tubular housing and operate by means of detecting movement of the housing relative to the aerosol canister on actuation of the dispenser by the patient. The indexing mechanism of the dose counter registers the actuation of the dispenser and the counter displays how many doses have been used or remain within the aerosol canister.
Some dose counters are detachable from the aerosol dispenser. One disadvantage of such devices is that the individual components may become separated and used in isolation from each other. Another disadvantage of these devices is that once the dose counter is removed from the aerosol canister it may be tampered with, typically by young children, to give a false reading. Detachment of the dose counter from the aerosol canister could therefore result in false readings on re-attachment to the canister. Furthermore, with patients having several different inhalers, the indicating device could be re-attached to the wrong dispenser.
Housings which could be used to reversibly secure such devices to aerosol containers, such as those described in FR 2 743 055 for use with gas and perfume canisters, suffer from the aforementioned disadvantages.
Other dose counters are essentially irreversibly attached to the aerosol dispenser.
One means of affixing dose counters to aerosol canisters is to use a ‘snap-fit’
AMENDED SHEET
CLEAN COPIES
~, mechanism whereby a tubular grip assembly on the dose counter housing is pushed into position around the neck of the valve ferrule thereby locking the two components together. Whilst this arrangement holds the two structures securely together there can, on occasions, be some lateral movement or ‘play’ of one component relative to the other. As mechanical dose counters operate by registering relative movement of the aerosol canister to the dose counter housing, any play or lateral movement can result in false readings being registered on the dose counter. A key factor in the successful operation and functioning of such dose counters is that there be minimal movement of the housing relative to the aerosol canister outwith the actuation cycle.
Dimensional variation resulting from manufacturing tolerances of aerosol canisters and dose counter housings poses additional problems in the assembly and operation of medicament dispensers. In order that the dose indicator mechanism functions correctly the canister and the counter housing must fit together tightly. Thus any variations in the dimensions of either of these components which result in a loose fit between the counter housing and the canister can lead to increased relative movement and the problems of false readings discussed above.
To overcome these problems of dimensional variation, stringent tolerance levels must be set for the manufacture of both the counter housing and the aerosol canister. This approach, together with the high levels of quality control necessary to ensure that both components meet the required engineering standards, is expensive for the manufacturer.
It is an object of the present invention to address the aforementioned problems associated with attachment of a mechanical or electrical device to an aerosol canister, in particular for the attachment of a dose counter housing thereto. The present invention involves joining the device housing to a ring or collar affixed around the neck of an aerosol canister to minimise the relative movement of the component parts. This joining can be achieved by a variety of technologies, including melting the components together by means of ‘hot staking’, soldering the
. PCT/EP00/09991 surfaces together, or using adhesives to bind the housing to the collar. Welding technologies are particulary well suited for this purpose.
According to the present invention there is provided a housing for a mechanical or electrical device for use with an aerosol canister for containing chemical comprising a collar affixable around the neck of the canister; a sleeve for receipt of the collar; and a joint between the sleeve and the collar to secure the housing to the canister.
In one aspect, the collar is a split collar.
In another aspect, the collar comprises the same material as the sieeve.
In a further aspect, the joint is a weld.
In yet another aspect, the weld is an ultrasound weld.
In a further aspect, the weld is a single continuous weld.
Optionally the weld comprises a plurality of spot welds. Preferably the number of welds is from 2 to 100, more preferably 6.
In another aspect, the weld is obtainable by energy generated by a sonitrode head, of energy output 100-200 Watts, frequency 20-50 kHz and duration 100-200 « milliseconds. A typical sonitrode head would be a converter.
In one aspect, the housing additionally comprises a mechanical or electrical device.
AMENDED SHEET
CLEAN COPIES
Preferably the mechanical or electrical device is a dose counter.
Preferably the electrical device is a sensor. 5 Preferably the sensor is for sensing the pressure profile associated with the breath cycle. Pressure transducers are suitable sensors of this type.
More preferably the sensor is for sensing the airflow profile associated with the breath cycle. Sprung vane sensors and sensors including anemometers are suitable sensors of this type.
More preferably the sensor is for sensing the temperature profile associated with the ] breath cycle. The temperature of the inhaled and exhaled part of the breath cycle varies and may, thus, be used as a measurement tool.
Is
Most preferably the sensor is for sensing the moisture profile associated with the breath cycle. The moisture content of the inhaled and exhaled part of the breath cycle varies and this also may be used as a measurement tool.
In a further aspect, the electrical device comprises a transceiver for transmitting and receiving data. Preferably, the transceiver comprises a radiofrequency identifier comprising an antenna for transmitting or receiving radiofrequency energy, and an integrated circuit chip connecting with said antenna.
The radiofrequency identifier can be any known radiofrequency identifier. Such identifiers are sometimes known as radiofrequency transponders or radiofrequency identification (RFID) tags or labels. Suitable radiofrequency identifiers include those sold by Phillips Semiconductors of the Netherlands under the trade marks Hitag and
Icode, those sold by Amtech Systems Corporation of the United States of America under the trade mark Intellitag, and those sold by Texas Instruments of the United
States of America under the trade mark Tagit.
Preferably the transceiver comprises a magnetic label or tag comprising an antenna for transmitting or receiving magnetic field energy; and an integrated circuit chip connecting with the antenna.
A suitable magnetic label or tag comprises plural magnetic elements in mutual association whereby the magnetic elements move relative to each other in response to an interrogating magnetic field. A magnetic label or tag of this type is described in
U.S. Patent No. 4,940,966. Another suitable magnetic label or tag comprises a magnetorestrictive element which is readable by application of an interrogating alternating magnetic field in the presence of a magnetic bias field which results in resonance of the magnetorestrictive elements at different predetermined frequencies. A magnetic label of this type is described in PCT Patent Application :
No. WO82/12402. Another suitable magnetic iabel or tag comprising plural discrete 1s magnetically active regions in a linear array is described in PCT Patent Application :
No. WQO96/31790. Suitable magnetic labels and tags include those making use of
Programmable Magnetic Resonance (PMR) (trade name) technology.
In another aspect, the electrical device comprises a microelectronic memory chip.
The microelectronic memory chip may be selected from the group consisting of programmable read only memory (PROM), erasable programmable read only memory (EPROM), electrically erasable programmable read only memory (EEPROM) and a SIM card-type memory chip. The microelectronic memory chip may alternatively be a random access memory (RAM) chip, powered by a suitable source such as a battery.
In one aspect, the housing additionally comprises a window for viewing a reading from the mechanical or electrical device. The reading may typically be in the form of a digital readout on a visual display unit or counter, or may take the form of a flashing coloured light to indicate, for example, the doses remaining within the canister.
PCT/EP00/09991
In another aspect of the present invention there is provided a method for securing a housing for a mechanical or electrical device to an aerosol canister comprising the sequential steps of placing a collar around the neck of the canister; positioning a sleeve around the collar; and joining the collar to the sleeve.
In one aspect the method additionally comprises associating the mechanical or electrical device with the sleeve. The device may be associated with the sleeve using a snap-fit mechanism. Preferably the method additionally comprises sealing the mechanical or electrical device within the sleeve. The device may be sealed within the sleeve using a range of sealing means, such as welding, soldering or adhesive means. Welding means are particularly suitable for sealing the device within the sleeve.
Preferably the method comprising inserting the mechanical or electrical device into the sleeve before joining the collar to the sleeve. More preferably the method comprises sealing the mechanical or electrical device within the sleeve before joining the collar to the sleeve.
Optionally the method comprises inserting the mechanical or electrical device into the housing after joining the collar to the sleeve. More preferably the method comprises sealing the mechanical or electrical device within the housing after joining the collar to the sleeve.
In one aspect, the device is a dose counter. In another aspect, the device is a sensor. In a further aspect, the device is a transceiver for transmitting or receiving data. In another aspect, the device is a microelectronic memory chip.
In one aspect, the collar is a split collar. Preferably, the collar comprises the same material as the sleeve around the canister.
AMENDED SHEET
CLEAN COPIES
In another aspect, the method comprises joining the collar to the sleeve by welding.
Preferably, the welding comprises ultra sound welding.
More preferably, the method comprises applying a single continuous weld. More preferably, the method comprises applying a plurality of spot welds. More preferably, it comprises applying from 2 to 100 welds, most preferably applying 6 welds.
In a further aspect, the method comprises using a sonitrode head to produce a weld condition of output 100 to 200 Watts, frequency 20 to 50 kilo Hertz and duration 100 to 200 milli seconds.
In another aspect of the present invention there is provided a dispenser comprising a housing according to the invention securable to an aerosol canister.
Preferably the dispenser additionally comprises an actuator body.
Preferably the dispenser is a medicament dispenser wherein the aerosol canister comprises a medicament in a propellant. More preferably the propellant is liquefied
HFA134a or HFA-227. Most preferably the medicament is selected from the group consisting of albuterol, salmeterol, ipratropium bromide, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any mixtures thereof.
The present invention further provides a kit of parts comprising a housing according to the present invention and an aerosol canister for containing chemical. Preferably the kit additionally comprising an actuator body. More preferably the chemical is a medicament.
In a further aspect of the present invention there is provided the use of medicament dispenser according to the present invention for the administration of medicament to a patient.
The invention will now be described with reference to the accompanying drawings in which:
Figure 1 is a schematic representation of a section through a standard metered dose inhalation device.
Figure 2 is a schematic representation of a section through an aerosol canister affixed to a housing according to the present invention.
Figure 3 is a schematic representation of a medical dispenser according to the 1s present invention.
Figures 4a - c is a schematic illustration of the process whereby a dose counter housing is secured to a standard metered dose inhalation device by ultrasound welding.
Figures 5a & b show a housing for a transceiver affixed to an aerosol container and a cross section of the housing according to the present invention.
The standard metered dose inhaler shown in Fig 1 comprises a housing 10 in which an aerosol canister 20 can be located. The housing is open at one end (which will hereinafter be considered to be the top of the device for convenience of description) and is closed at the other. An outlet 30 leads laterally from the closed end of the housing 10. In the embodiment illustrated, the outlet 30 is in the form of a mouthpiece intended for insertion into the mouth of the patient but it may, if desired, be designed as a nozzle for insertion into the patient's nostril.
The aerosol canister 20, comprising a neck region 21 and ferrule 22, has an outlet valve stem 40 at one end. This valve member can be depressed to release a measured dose from the aerosol canister or, alternatively, the valve stem 40 can be fixed and the main body of the canister can be moved relative to the valve member to release the dose.
As shown in Figure 1, the aerosol canister 20 is located in the housing 10 so that one end protrudes from its open top, the canister being positioned such that the neck 21 and valve ferrule 22 are enclosed within housing 10. Spacer ribs (not shown) may be provided inside the housing to hold the external surface of the canister 20 spaced from the internal surface of the housing 10. A support 50 is provided at the lower end of the housing 10 and has a passage 60 in which the valve stem 40 of the aerosol canister 20 can be located and supported. A second passage 70 is provided in the support 50 and is directed towards the interior of the outlet 30. Thus, when the parts are in the positions shown in Figure 1, the protruding portion of the aerosol canister 20 can be depressed to move the canister relative to the valve stem 40 to open the valve and a dose of medicament contained in the aerosol will be discharged through the passage 70 and into the outlet 30 from which it can be inhaled by a patient. One dose will be released from the aerosol canister each time it is fully depressed.
Figure 2 is a schematic diagram showing a housing for a dose indicating device 100 (internal details not shown) connected to an aerosol canister 120 according to the present invention. The housing comprises a cradle 101 for supporting the counter mechanism, located within the body of the counter (details not shown), and a housing 100 having a tubular sleeve 102 to receive aerosol canister 120 and valve stem 140. Collar 125, which is typically a split ring, is secured around the neck 121 of the aerosol canister 120. Tubular sleeve 102 fits over valve ferrule 122 and engages collar 125 which is tightly affixed around neck 121 of aerosol canister 120.
Thus the tubular sleeve 102 and collar 125 form a tight connection between housing 100 and aerosol canister 120. Collar 125 is welded to sleeve 102 by application of ultrasound energy. The sieeve 102 is secured to the collar 125 by a series of spot s welds 180. Two sonitrodes (not shown) are generally employed in the welding process, each sonitrode having three pins which are pushed into contact with the sleeve 102. Energy is transferred through the sonitrode pins, causing them to vibrate and fusing the sleeve 102 to the collar 125. The vibrating pins are pushed through the sleeve 102 to a depth of approximately 2mm into the body of the collar 125, melting and fusing the materials together, to form a series of spot welds. In an alternative herein, one continuous weld may be employed by either moving the sonitrode head around the sleeve or vice versa. } Figure 3 is a schematic diagram showing the lower part of a device similar to that of ~ 15 Figure 1 but incorporating the housing for a dose indicating device 200 affixed to an : aerosol canister according to the invention as shown in Figure 2. The counter mechanism (not shown) is supported on a cradle 201 and engages post 218.
Ultrasound welds 280 secure collar 225 around neck 221 of canister 220 to tubular sleeve 202, thereby affixing aerosol canister 220 to dose counter housing 200. The resulting assembly is positioned within housing 210. Thus on depression of the aerosol canister 220, the canister moves relative to the valve stem 240 and opens the canister valve (not shown) to discharge a predetermined dose of medicament to the patient through valve stem 240 and thence to outlet 230. The relative movement of canister 220 to counter housing 200 is registered by the counter mechanism (not 25s shown) and the number of doses of medicament used or remaining within canister 220 is displayed on counter window 205 and can be viewed through housing window 215.
Figures 4a — c illustrate, with another embodiment of the present invention, the process whereby the collar 325 is fitted around neck 321 of the canister 320 and welded to tubular sleeve 302 of the dose counter housing 300. Figure 4a is an exploded diagram showing collar 325 being positioned between canister 320 and dose counter housing 300 displaying counter window 305. The collar 325 is slipped around neck 321 of canister 320 (Figure 4b). As shown in Figure 4c, the collar 325 is then pushed in the direction of arrow A to locate against the base of ferrule 322 at the top of neck 321, while dose counter housing 300 is positioned over the top of canister 320 by being pressed down in the direction of arrow B. In this way, collar 325 is wedged between tubular sleeve 302 and the neck of canister 321. The collar 325 is joined to tubular sleeve 302 by ultra sound welding at the points indicated by arrows C, thereby securing the dose counter housing 300 to canister 320.
Figures 5a and §b show a housing 400 for a passive transceiver in the form of an electrically erasable programmable read only memory (EEPROM) chip 490. In
Figure 5a the housing 400 is welded at points 480 to collar 425 (not shown) which has been secured to the neck 421 of the aerosol canister 420 having outlet 440 as described above. The chip 490, located within housing 400, communicates with electrical contact pad 495. Figure 5b is a cut-away section of Figure 5a, the aerosol canister having been removed to show collar 425 welded to housing 400. In this sectional view, EEPROM chip 490 and electrical contact pad 495 are clearly shown.
Whilst the present invention has been described in detail in respect of a metered dose inhaler it will be appreciated that other mechanical and electronic devices, such as electronic sensors and readers, may be attached to an aerosol canister in an identical manner. For example, a temperature/pressure sensor for use with a paint dispenser could also be affixed to the aerosol canister in this way.
It may be appreciated that any of the parts of the dispenser which contact the chemical suspension may be coated with materials such as fluoropolymer materials which reduce the tendency of chemical to adhere thereto. Any movable parts may also have coatings applied thereto which enhance their desired movement characteristics. Frictional coatings may therefore be applied to enhance frictional : contact and lubricants used to reduce frictional contact as necessary.
The medicament dispenser of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease.
Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate (e.g. s the sodium salt), ketotifen or nedocromil (e.g. as the sodium salt); antiinfectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-
inflammatories, e.g., beclomethasone (e.g. as the dipropionate ester), fluticasone (e.g. as the propionate ester), flunisolide, budesonide, rofleponide, mometasone e.g. as the furoate ester), ciclesonide, triamcinolone (e.g. as the acetonide) or 6a, 9a- difluoro-11p-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-diene-178- carbothioic acid S-(2-oxo-tetrahydro-furan-3-yl) ester; antitussives, e.g., noscapine;
bronchodilators, e.g., albutero! (e.g. as free base or sulphate), salmeterol (e.g. as xinafoate), ephedrine, adrenaline, fenoterol (e.g. as hydrobromide), formoterol (e.g. as fumarate), isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol (e.g. as acetate), reproterol (e.g. as hydrochloride), rimiterol, terbutaline (e.g. as sulphate), isoetharine, tulobuterol or 4-hydroxy-7-[2-[[2-[[3-(2-
phenylethoxy)propyl]sulfonyllethyllamino]ethyl-2(3H)-benzothiazolone; adenosine 2a agonists, e.g. 2R,3R,4S,5R)-2-[6-Amino-2-(1S-hydroxymethyl-2-phenyl-ethylamino)- purin-9-yl}-5-(2-ethyi-2H-tetrazoi-5-yl)-tetrahydro-furan-3,4-diof (e.g. as maleate); a4 integrin inhibitors e.g. (2S)-3-[4-({[4-(aminocarbonyl)-1-piperidinyl] carbonyl}oxy)phenyl]-2-[((2S)-4-methyi-2-{[2-(2-methylphenoxy)
acetyllamino}pentanoyl)amino] propanoic acid (e.g. as free acid or potassium salt), diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium (e.g. as bromide), tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon; vaccines, diagnostics and gene therapies.
It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form
' PCT/EP00/09991 of salts, (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant. Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g. the sulphate of albuterol and the xinafoate of salmeterol.
Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g. as the free base of the sulphate salt) or salmeterol (e.g. as the xinafoate salt) or formoterol (e.g. as the fumarate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g. the dipropionate) or a fluticasone ester (e.g. the propionate) or budesonide. A particularly preferred combination is a combination of fluticasone propionate and salmeterol, or a salt thereof (particularly the xinafoate salt). A further combination of particular interest is budesonide and formoterol (e.g. as the fumarate salt).
It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.
AMENDED SHEET
CLEAN COPIES
Claims (55)
1. A housing for a mechanical or electrical device for use with an aerosol canister for containing chemical comprising a collar affixable around the neck of said canister; a sleeve for receipt of said collar; and a joint between said sleeve and the collar to secure said housing to the canister, in which the collar is a split collar.
2. Housing according to claim 1, wherein the collar comprises the same : material as the sleeve.
3. Housing according to either of claims 1 or 2, wherein said joint is a weld.
4, Housing according to claim 3, wherein said weld is an ultrasound weld.
5. Housing according to either of claims 3 or 4, wherein the weld is a single continuous weld.
6. Housing according to either of claims 3 or 4, wherein the weld comprises a plurality of spot welds.
7. Housing according to claim 6, wherein the number of welds is from 2 to
100.
8. Housing according to claim 7, wherein the number of welds is 6.
9. Housing according to any of claims 3 to 8, wherein the weld is obtainable by energy generated by a sonitrode head, of energy output 100- 200 Watts, frequency 20-50 kilo Hertz and duration 100 -200 milliseconds. AMENDED SHEET k B PCT/EP00/09991
10. Housing according to any of the preceding claims , additionally comprising said mechanical or electrical device.
11. Housing according to any of the preceding claims, wherein the mechanical or electrical device is a dose counter.
12. Housing according to any of the preceding claims, wherein the electrical device is a sensor.
13. Housing according to claim 12, wherein said sensor is for sensing the pressure profile associated with the breath cycle.
14. Housing according to claim 12, wherein the sensor is for sensing the airflow profile associated with the breath cycle.
15. Housing according to claim 12, wherein the sensor is for sensing the temperature profile associated with the breath cycle.
16. Housing according to claim 12, wherein the sensor is for sensing the moisture profile associated with the breath cycle. :
17. Housing according to any of the preceding claims, wherein the electrical device comprises a transceiver for transmitting and receiving data.
18. Housing according to any of the preceding claims, wherein the electrical device comprises a microelectronic memory chip.
19. Housing according to claim 18, wherein said chip is selected from the group consisting of random access memory (RAM), programmable read only memory (PROM), erasable programmable read only memory (EPROM), AMENDED SHEET
- PCT/EP00/09991 electrically erasable programmable read only memory (EEPROM) and a SIM card-type memory chip.
20. Housing according to any of the preceding claims, additionally comprising a window for viewing a reading from the mechanical or electrical device.
21. Method for securing a housing for a mechanical or electrical device to an aerosol canister comprising the sequential steps of placing a collar around the neck of said canister; positioning a sleeve around said collar; and joining the collar to said sleeve.
22. Method according to claim 21, additionally comprising associating said mechanical or electrical device with said sleeve.
23. Method according to claim 22, additionally comprising sealing the mechanical or electrical device within the sleeve.
24. Method according to claim 22, comprising inserting the mechanical or electrical device into the sleeve before joining the collar to the sleeve.
25. Method according to claim 24, comprising sealing the mechanical or electrical device within the sleeve before joining the collar to the sleeve.
26. Method according to claim 22, comprising inserting the mechanical or electrical device into the housing after joining the collar to the sleeve.
27. Method according to claim 26, comprising sealing the mechanical or electrical device into the housing after joining the collar to the sleeve. AMENDED SHEET
; PCT/EP00/09991
28. Method according to any of claims 22 or 27, wherein the device is a dose counter.
29. Method according to any of claims 22 to 28, wherein the device is a sensor.
30. Method according to any of claims 22 to 29, wherein the device is a transceiver for transmitting or receiving data.
31. Method according to any of claims 22 to 30, wherein the device is a microelectronic memory chip.
32. Method according to any of claims 21 to 31, wherein the collar is a split collar.
33. Method according to any of claims 21 to 32, wherein the collar comprises the same material as the sleeve around the canister.
34. Method according to any of claims 21 to 33, comprising joining the collar to the sleeve by welding.
35. Method according to claim 34, wherein said welding comprises ultra sound welding.
36. Method according to either of claims 34 or 35, comprising applying a single continuous weld.
37. Method according to either of claims 34 or 35, comprising applying a plurality of spot welds.
38. Method according to claim 37, comprising applying from 2 to 100 welds. AMENDED SHEET
. - PCT/EP00/09991
39. Method according to either of claims 37 or 38, comprising applying 6 welds.
40. Method according to any of claims 34 to 39, comprising using a sonitrode head to produce a weld condition, of output 100 to 200 Watts, frequency 20 to 50 kilo Hertz and duration 100 to 200 milli seconds.
41. Dispenser comprising a housing according to any of claims 1 to 20 securable to an aerosol canister.
42. Dispenser according to claim 41, additionally comprising an actuator body.
43. Medicament dispenser according to either of claims 41 or 42, wherein said aerosol canister comprises a medicament in a propellant.
44. Medicament dispenser according to claim 43, wherein said propellant is liquefied HFA134a or HFA-227.
45. Medicament dispenser according to claim 43, wherein said medicament is selected from the group consisting of albuterol, salmeterol, ipratropium bromide, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any mixtures thereof.
46. Kit of parts comprising a housing according to any of claims 10 to 20; and an aerosol canister for containing chemical.
47. Kit of parts according to claim 46, additionally comprising an actuator } body. AMENDED SHEET
. PCT/EPO0/09991
48. Kit of parts according to either of claims 46 or 47, wherein said chemical is a medicament.
49. Use of medicament dispenser according to any of claims 43 to 45 for the administration of medicament to a patient.
50. A housing according to claim 1, substantially as herein described and illustrated.
51. A method according to claim 21, substantially as herein described and illustrated.
52. A dispenser according to claim 41, substantially as herein described and illustrated.
53. Akit according to claim 46, substantially as herein described and : illustrated.
54. Use according to claim 49, substantially as herein described and illustrated.
55. A new housing, a new method for securing a housing, a new dispenser, a new kit of parts, or a new use of a dispenser as claimed in any one of claims 43 to 45, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924468.3A GB9924468D0 (en) | 1999-10-16 | 1999-10-16 | Dose counter housing |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200201608B true ZA200201608B (en) | 2003-05-26 |
Family
ID=10862831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200201608A ZA200201608B (en) | 1999-10-16 | 2002-02-26 | Device housing for an aerosol container. |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB9924468D0 (en) |
ZA (1) | ZA200201608B (en) |
-
1999
- 1999-10-16 GB GBGB9924468.3A patent/GB9924468D0/en not_active Ceased
-
2002
- 2002-02-26 ZA ZA200201608A patent/ZA200201608B/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB9924468D0 (en) | 1999-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9861771B2 (en) | Device housing for an aerosol container | |
US7819116B2 (en) | Medicament dispenser | |
US7467629B2 (en) | Medicament dispenser with magneto-rheological fluid actuator | |
US8240301B2 (en) | Dispensing device | |
US6981499B2 (en) | Medicament dispenser | |
EP1255580B1 (en) | Housing for an inhaler | |
ZA200201608B (en) | Device housing for an aerosol container. | |
HK1051350B (en) | Device housing for an aerosol container | |
ZA200209369B (en) | Medicamment dispenser. |